MRI management of NMOSD and MOGAD: Proposals from the French Expert Group NOMADMUS
Journal of Neuroradiology. 2025-02-01; 52(1): 101235
DOI: 10.1016/j.neurad.2024.101235
Lire sur PubMed
https://www.bordeaux-neurocampus.fr/12326
Durand-Dubief F(1), Shor N(2), Audoin B(3), Bourre B(4), Cohen M(5), Kremer S(6), Maillart E(7), Papeix C(8), Ruet A(9), Savatovsky J(10), Tourdias T(11), Ayrignac X(12), Ciron J(13), Collongues N(14), Laplaud D(15), Michel L(16), Deschamps R(8), Thouvenot E(17), Zephir H(18), Marignier R(19), Cotton F(20);
NOMADMUS Study Group.
Author information:
(1)Service de Sclérose en Plaques, Pathologies de la substance blanche et
Neuroinflammation, Hôpital Neurologique, Hospices Civils de Lyon, Bron, France;
Creatis LRMN, CNRS UMR 5220, Université Claude Bernard Lyon 1, INSERM U630,
Lyon, France. Electronic address: .
(2)Service de Neuroradiologie, Hôpital de la Pitie-Salpetrière, AP-HP, Paris,
France.
(3)Service de Neurologie, Maladies Inflammatoires du Cerveau et de la Moelle
Épinière (MICeME), Hôpital de la Timone, AP-HM, Marseille CEDEX 5, France.
(4)Service de Neurologie, Centre Hospitalier Universitaire Rouen, Rouen F-76000,
France.
(5)CRC-SEP, Neurologie Pasteur 2, CHU de Nice, Nice, France; Université Cote
d’Azur, UMR2CA (URRIS), Nice, France.
(6)Service d’imagerie 2, Hôpital de Hautepierre, Hôpitaux Universitaires de
Strasbourg, Strasbourg, France; Engineering Science, Computer Science and
Imaging Laboratory (ICube), Integrative Multimodal Imaging in Healthcare, UMR
7357, University of Strasbourg-CNRS, Strasbourg, France.
(7)Service de Neurologie, Hôpital de la Pitie-Salpetrière, Centre de Références
des Maladies Inflammatoires Rares du Cerveau Et de la Moelle épinière, AP-HP,
Paris, France.
(8)Service de Neurologie, Hôpital Fondation Adolphe de Rothschild, Paris,
France.
(9)Service de Neurologie et Maladies inflammatoires du Système nerveux Central,
Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Université de
Bordeaux, INSERM, Neurocentre Magendie, U1215, Bordeaux, France.
(10)Service d’Imagerie Médicale, Hôpital Fondation Adolphe de Rothschild, Paris,
France.
(11)Neuroimagerie Diagnostique et Thérapeutique, Centre Hospitalier
Universitaire de Bordeaux, Bordeaux F-33000, France; Université Bordeaux,
INSERM, Neurocentre Magendie, U1215, Bordeaux F-3300, France.
(12)Université de Montpellier, Montpellier, France; Département de Neurologie,
CRC-SEP, CRMR LEUKOFRANCE, Hôpital Gui de Chauliac, Centre Hospitalier
Universitaire de Montpellier, France.
(13)Service de Neurologie, CRC-SEP, Centre Hospitalier Universitaire de
Toulouse, France.
(14)Service de Neurologie, Centre Hospitalier Universitaire de Strasbourg,
Strasbourg, France; Center for Clinical Investigation, INSERM U1434, Strasbourg,
France; Department of Pharmacology, Addictology, Toxicology, and Therapeutics,
Strasbourg University, Strasbourg, France.
(15)Center for Research in Transplantation and Translational Immunology, Nantes
Université, INSERM, CHU de Nantes, UMR 1064, CIC INSERM 1413, Service de
Neurologie, Nantes F-44000, France.
(16)Service de Neurologie, Centre Hospitalier Universitaire de Rennes, Rennes,
France; Clinical Neuroscience Centre, University Hospital, Rennes University,
CIC_P1414 INSERM, Rennes, France.
(17)Service de Neurologie, Centre Hospitalier Universitaire de Nîmes, Nîmes,
France; Institut de Génomique Fonctionnelle, Université Montpellier, CNRS
INSERM, Montpellier, France.
(18)CCMR MIRCEM, Université de Lille INSERM U1172, CHU de Lille, Lille, France;
CCMR MIRCEM, CHU de Lille, Lille, France.
(19)Service de Sclérose en Plaques, Pathologies de la substance blanche et
Neuroinflammation, Hôpital Neurologique, Hospices Civils de Lyon, Bron, France.
(20)Service de Radiologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon,
Pierre-Bénite, France; Creatis LRMN, CNRS UMR 5220, Université Claude Bernard
Lyon 1, INSERM U630, Lyon, France.
BACKGROUND: Currently, there are no available recommendations or guidelines on
how to perform MRI monitoring in the management of neuromyelitis optica spectrum
disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated
disease (MOGAD). The issue is to determine a valuable MRI monitoring protocol to
be applied in the management of NMOSD and MOGAD, as previously proposed for the
monitoring of multiple sclerosis.
OBJECTIVES: The objectives of this work are to establish proposals for a
standardized and feasible MRI acquisition protocol, and to propose control time
points for systematic MRI monitoring in the management of NMOSD and MOGAD.
METHODS: A steering committee composed of 7 neurologists and 5
neuroradiologists, experts in NMOSD and MOGAD from the French group NOMADMUS,
defined 8 proposals based on their expertise and a review from the literature.
These proposals were then submitted to a Rating Group composed of French NMOSD /
MOGAD experts.
RESULTS: In the management of NMOSD and MOGAD, a consensus has been reached to
perform systematic MRI of the brain, optic nerve and spinal cord, including
cauda equina nerve roots, at the time of diagnosis, both without and after
gadolinium administration. Moreover, it has been agreed to perform a systematic
MRI scan 6 months after diagnosis, focusing on the area of interest, both
without and after gadolinium administration. For long-term follow-up of NMOSD
and MOGAD, and in the absence of clinical activity, it has been agreed to
perform gadolinium-free MRI of the brain (+/- optic nerves) and spinal cord,
every 36 months. Ideally, these MRI scans should be performed on the same MRI
system, preferably a 3T MRI system for brain and optic nerve MRI, and at least a
1.5T MRI system for spinal cord MRI.
CONCLUSIONS: This expert consensus approach provides physicians with proposals
for the MRI management of NMOSD and MOGAD.
Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights
reserved.
DOI: 10.1016/j.neurad.2024.101235
PMID: 39626832 [Indexed for MEDLINE]
Conflict of interest statement: Declaration of competing interest Françoise
DURAND-DUBIEF has nothing to disclose. Natalia SHOR has nothing to disclose.
Bertrand AUDOIN has nothing to disclose. Bertrand BOURRE serves on scientific
advisory board, has received funding for travel and honoraria from Alexion,
Biogen, BMS, Horizon, Janssen, Merck, Novartis, Sanofi, Sandoz and Roche. Mikael
Cohen has received personal compensation for consulting, serving on a scientific
advisory board, speaking, or other activities with Biogen, Merck, Sanofi, Roche,
Celgene-BMS, Janssen, Alexion, Horizon Therapeutics and Ad Scientiam. Stéphane
KREMER has nothing to disclose. Elisabeth MAILLART reports research support from
Biogen and personal fees for lectures and advisory boards from Alexion, Biogen,
Horizon, Janssen, Merck, Novartis, Roche, Sanofi, and Teva. Caroline PAPEIX has
received personal compensation for consulting, serving on a scientific advisory
board, speaking from Alexion, Horizon, Roche. Aurélie RUET has received funding
for travel or speaker or consultant honoraria from Biogen, Alexion, Novartis,
Sanofi, Merck, Horizon Therapeutic; and received research support from Biogen,
BMS, Sanofi, Roche, Merck. Julien SAVATOVSKY has nothing to disclose. Thomas
TOURDIAS has nothing to disclose. Xavier AYRIGNAC has received consulting fees
and lecturing fess, travel grants and undoncitional research support from
Alexion, Biogen, Genzyme, Janssen, Merck Serono, Novartis, Roche, Sanofi Aventis
and Teva Pharma. Jonathan CIRON has received personal compensation for
consulting, serving on a scientific advisory board, speaking, or other
activities with Biogen, Novartis, Merck, Sanofi, Roche, Alexion, Horizon
Therapeutics, none related to this study. Nicolas COLLONGUES has received
honoraria for consulting or presentation from Alexion, Biogen Idec,
Bristol-Myers Squibb, Horizon Therapeutics, Merck Serono, Novartis, Roche and
Sanofi-Genzyme and is a member of the Editorial Board of the Journal de la Ligue
Française contre la Sclérose en plaques and the Neurology and Therapy Journal.
David LAPLAUD served on scientific advisory boards for Alexion, BMS, Roche,
Sanofi, Novartis, Merck, Janssen and Biogen, received conference travel support
and/or speaker honoraria from Alexion, Novartis, Biogen, Roche, Sanofi, BMS and
Merck and received research support from Fondation ARSEP, Fondation EDMUS and
Agence Nationale de la Recherche. Laure MICHEL has nothing to disclose. Romain
DESCHAMPS has received personal compensation for serving on a scientific
advisory board or travel grants from Biogen, Roche, Alexion, and Novartis. Eric
THOUVENOT received consulting and lecturing fees, travel grants or unconditional
research support from Actelion, Biogen, BMS, Merck, Novartis, Roche, Teva
pharma. Hélène ZEPHIR received consulting fees and invitation for congresses
from Alexion, Horizon Therapeutics, Roche, Sanofi, Janssen, Biogen Idex, Merck,
BMS. HZ received research supports from Novartis, Roche. Romain MARIGNIER serves
on scientific advisory boards for Horizon Therapeutics/Amgen; and has received
funding for travel and fees from Alexion, Amgen Biogen, Roche, Sanofi. François
COTTON reports grants, consulting fees, and non-financial support from Biogen,
Bracco imaging, Merck-Serono, Novartis, Philips and Roche.